Deppe Michael J sold $3.1M of DGX

Deppe Michael J (SVP, Corp. Controller & CAO) sold 11,776 shares of QUEST DIAGNOSTICS INC (DGX) at $260.17 ($3.06M total) across 2 trades on 2026-11-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Deppe Michael J
Published Nov 16, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Neutral
high confidence
Mentioned
$DGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

The disclosure provides transparency on insider selling activity but does not include any new DGX business, financial, or regulatory developments.

02

Market read

Traders may monitor insider activity for sentiment, but the pre-arranged 10b5-1 nature reduces the likelihood of a material price reaction.

03

What to watch

10b5-1 plans are often set months in advance for diversification or tax planning, so the sale timing may not reflect current views on DGX.

Relevance 5/10Novelty 4/10Timing: filing reported after-hours on 2026-11-16, covering trades dated 2026-11-13

Background

The article is an SEC Form 4 insider transaction disclosure for Quest Diagnostics (DGX).

Company-level read

Ticker impact

$DGXNeutralHigh confidence
Context

SEC Form 4 shows DGX SVP Michael J Deppe sold 11,776 shares for about $3.06M under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact as the sale is pre-arranged under 10b5-1, with any effect confined to marginal sentiment.

Evidence & confidence

The filing specifies an S (open-market sale) and confirms a pre-arranged 10b5-1 plan; insider sales of this type are often routine and not indicative of new company fundamentals.

Market effects

Minimal, as this is a single-company insider transaction with no operational or guidance change.

None.

None.

Counterpoint

Some traders may read insider selling as a signal of reduced confidence, even if it is 10b5-1, and use it as a minor risk flag.

Key entities

  • Quest Diagnostics

    DGX, the company whose insider transaction is disclosed.

  • Michael J. Deppe

    SVP, Corporate Controller & CAO who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.